Published in PLoS Comput Biol on April 01, 2016
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy. Front Pharmacol (2016) 0.76
Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model. NPJ Syst Biol Appl (2017) 0.75
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
PID: the Pathway Interaction Database. Nucleic Acids Res (2008) 12.92
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics (2009) 12.01
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell (2012) 5.92
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
Histone deacetylase inhibitors in cancer therapy. J Clin Oncol (2009) 4.58
Discovering motifs in ranked lists of DNA sequences. PLoS Comput Biol (2007) 4.40
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol (2013) 3.57
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
Inconsistency in large pharmacogenomic studies. Nature (2013) 3.46
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol (2006) 3.01
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol (2014) 2.12
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res (2012) 1.87
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res (2012) 1.86
The clinical development of MEK inhibitors. Nat Rev Clin Oncol (2014) 1.79
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data (2014) 1.76
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res (2010) 1.59
Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med (2012) 1.57
Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol (2014) 1.28
Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci Signal (2013) 1.17
Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol (2008) 1.15
Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res (2011) 1.13
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw (2013) 1.11
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal (2013) 1.07
Using network biology to bridge pharmacokinetics and pharmacodynamics in oncology. CPT Pharmacometrics Syst Pharmacol (2013) 1.03
BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry (2012) 0.96
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J (2012) 0.94
Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin Oncol (2008) 0.87
Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol (2013) 0.85
From cancer genomics to precision oncology--tissue's still an issue. Cell (2014) 0.81
Dissociated presenilin-1 and TACE processing of ErbB4 in lung alveolar type II cell differentiation. Biochim Biophys Acta (2014) 0.80
Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells. Breast Cancer Res Treat (2009) 0.80
Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines. BMC Syst Biol (2014) 0.77
Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers. CPT Pharmacometrics Syst Pharmacol (2015) 0.76